TrialPloS one2019

Tailored NEOadjuvant epirubicin, cyclophosphamide and Nanoparticle Albumin-Bound paclitaxel for breast cancer: The phase II NEONAB trial-Clinical outcomes and molecular determinants of response.

Caitlin Murphy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.